BridgeBio Pharma vs Sarepta Therapeutics
BBIO and SRPT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BBIO and SRPT compare
BridgeBio Pharma is the larger company, worth 7.4 times as much as Sarepta Therapeutics ($14.7B against $2.0B).
BridgeBio Pharma grew revenue faster over the last twelve months (167% versus −20.4% for Sarepta Therapeutics).
Sarepta Therapeutics scores higher on the StockData Score (12 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BBIO | SRPT |
|---|---|---|
| Size and price | ||
| Market cap | $14.7B | $2.0B |
| Share price | $74.95 | $18.62 |
| Change, 1 year | 12.5% | −20.6% |
| Change, 5 years | 40.3% | −79.1% |
| Beta (5Y) | 1.13 | 1.02 |
| Employees | 834 | 835 |
| StockData Score | ||
| Total score | 3 | 12 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 3 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.5× | 1.0× (better) |
| P/B | – | 1.3× |
| P/FCF | – | 24.0× |
| FCF yield | −2.5% | 4.2% (better) |
| Fair value | – | $109.03 |
| Margin of safety | – | 82.9% |
| Growth | ||
| Revenue growth (TTM) | 167% (better) | −20.4% |
| Revenue growth, 5Y average | 127% (better) | 32.4% |
| Profitability | ||
| Gross margin | 94.3% | – |
| Operating margin | −38.5% | −7.3% (better) |
| Net margin | – | −6.9% |
| FCF margin | −39.1% | 4.1% (better) |
| Return on equity | – | −9.3% |
| Return on invested capital | – | −16.8% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −7.1× | – |
| Current ratio | 2.09 | 4.42 (better) |
| Altman Z-score | 0.06 (better) | −0.17 |
| Piotroski F-score | – | 3 |
| Dividends and buybacks | ||
| Buyback yield | 1.7% | – |
| Shareholder yield | 1.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 99.1% | 102% |
| Held by insiders | 35.5% | 5.9% |
| Insider net buying, 12 months | −$105M | −$417K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 15.6% | 22.9% |
Go deeper
- BBIO stock overview
- BBIO income statement
- BBIO valuation and score
- SRPT stock overview
- SRPT income statement
- SRPT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.